Browse > Article
http://dx.doi.org/10.6564/JKMRS.2012.16.2.133

Identification of Derivatives of Cobalt-binding BLM-A2 by NMR  

Lee, Seongeon (Department of Applied Chemistry, Hanyang University)
Shin, Donghyuk (Department of Applied Chemistry, Hanyang University)
Woo, Sunhee (Department of Applied Chemistry, Hanyang University)
Won, Hoshik (Department of Applied Chemistry, Hanyang University)
Publication Information
Journal of the Korean Magnetic Resonance Society / v.16, no.2, 2012 , pp. 133-146 More about this Journal
Abstract
Three different derivatives were obtained in the synthesis of cobalt-binding BLM-A2 and characterized by NMR and Mass spectrometry. It was found that Component 1 is Co(II)($2H_2O$)(BLM-A2), component 2 is Co(III)($OOH^-$)(BLM-A2) and component 3 is Co(III)($H_2O$)($OH^-$)(BLM-A2), respectively. Component 2 and 3 were interestingly dominated when CoBLM-A2 complex was synthesized under basic condition. In this experiment, it was revealed newly that the brown form (component 1) was 6-coordinated structure composed with not 5 ligands but 4 ligands from BLM-A2 and with $2H_2O$ as the axial ligands. The component 3 exhibiting a novel ligand configuration is found, and the structure of component 3 was observed to be very similar to that of component 1 in the kind of their ligands but one of the axial ligand is $OH^-$ instead of $H_2O$. These ligand configurations are different from the green form (component 2) exhibiting 6-coordinate structure composed of 5 ligands from BLM-A2 and one ligand of $OOH^-$, being consistent with former studies.
Keywords
Bleomycin; NMR; Cobalt-binding BLM-A2; Purification;
Citations & Related Records
연도 인용수 순위
  • Reference
1 H. Umezawa, K. Maeda, T. Takeuchi, Y. Okami, J. Antibiot. 19A, 200 (1966).
2 H. Umezawa, Bleomycin: Current Status and New Developments, Academic Press, New York. 15 (1978).
3 B. I. Sikic, Bleomycin Chemotherapy, Academic Press, Orlando, FL. (1985).
4 J. Stubbe, J. W. Kozarich, Chem. Rev. 87, 1107 (1987).   DOI
5 A. Natrajan, S. M. Hecht, Molecular Aspects of Anticancer Drug-DNA Interactions Vol. 2, MacMillan Press, London. 97 (1993).
6 S. A. Kane, S. M. Hecht, Prog. Nucleic Acid Res. Mol. Biol. 49, 313 (1994).   DOI
7 S. M. Hecht, Bioconjugate Chem. 5, 513 (1994).   DOI
8 S. M. Hecht, Cancer Chemotherapeutic Agents Foye, W., Ed. American Chemical Society, Washington, DC. 369 (1995).
9 D. H. Petering, R. W. Byrnes, W. E. Antholine, Chem. Biol. Interact. 73, 133 (1990).   DOI
10 J. C. Dabrowiak, Adv. Inorg. Chem. 4, 69 (1982).
11 A. H. Thomas, P. Newland, N. R. Sharma, J. Chromatogr. 337, 219 (1984).
12 R. P. Klett, J. P. Chovan, J. Chromatogr. 337, 182 (1985).   DOI
13 M. A. J. Akkerman, E. W. J. F. Neijman, S. S. Wijmenga, C. W. Hilbers, W. Bermel, J. Am. Chem. Soc. 112, 7462 (1990).   DOI
14 W. Wu, D. E. Vanderwall, S. M. Lui, X. J. Tang, C. J. Turner, J. W. Kozarich, J. Stubbe, J., J. Am. Chem. Soc. 118, 1268 (1996).   DOI
15 S. M. Lui, D. E. Vanderwall, W. Wu, X. J. Tang, C. J. Turner, J. W. Kozarich, J. Stubbe, J. J. Am. Chem. Soc. 119, 9603 (1997).   DOI
16 M. A. J. Akkerman, C. A. G. Haasnoot, C. w. Hilbers, Eur. J. Biochem. 173, 211 (1988).   DOI
17 P. Fulmer, C. Q. Zhao, W. B. Li, E. Derose, W. E. Antholine, D. H. Petering, Biochemistr 36, 4367 (1997).   DOI
18 J. Cacerescortes, H. Sugiyama, K. Ikudome, I. Saito, A. H. J. Wang, Eur J. Biochem. 244, 818 (1997).   DOI
19 D. Kim, M. Lee, C. Lee, H. Won, H., J. Kor. Mag. Reson. 10, 163 (2006).
20 Y. Iitaka, H. Nakamura, T. Nakatani, Y. Muraoka, A. Fujii, T. Takita, H. Umezawa, J. Antibiot. 31, 1070 (1978).   DOI
21 D. Kim. H. Won, J. Kor. Mag. Reson. 2, 50 (1998)